GlassScriptPhysician profile
Aaron R Parry
NPI 1982864799
$165,410.01
in general payments reported to CMS, 2019-2025
44 companies · $1,584 in 2025
The $1,584 reported for 2025 was more than what 94% of Obstetrics providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $43K · 2020: $21K · 2021: $70K · 2022: $17K · 2023: $8,765 · 2024: $4,836 · 2025: $1,584.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $9,063 · Food and Beverage: $4,035 · Travel and Lodging: $1,987 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $9,062.50 |
| Food and Beverage | $4,035.03 |
| Travel and Lodging | $1,987.12 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $154,886.22 | 2019-2025 | |
| Acessa Health INC. | $3,812.50 | 2024 | Acessa Provu System |
| Intuitive Surgical, INC. | $1,126.59 | 2023 | Da Vinci Surgical System, Da Vinci Sp |
| Mayne Pharma Commercial LLC | $829.50 | 2021-2025 | |
| Shield Therapeutics INC | $521.07 | 2022-2025 | Accrufer |
| Bayer Healthcare Pharmaceuticals INC. | $427.00 | 2019-2025 | |
| Hologic Sales and Service, LLC | $395.61 | 2019-2025 | Acessa Provu System, Aptima, Thinprep 2000 Processor |
| Astellas Pharma US INC | $368.86 | 2022-2025 | Veozah, Myrbetriq |
| Exeltis, USA INC. | $300.91 | 2020-2024 | Slynd |
| Sumitomo Pharma America, INC. | $287.84 | 2024-2025 | Myfembree, Gemtesa |
| Therapeuticsmd, INC. | $248.08 | 2019-2022 | |
| Sage Therapeutics, LLC | $245.66 | 2022-2025 | Zurzuvae |
| Millicent US INC | $201.70 | 2019-2025 | Intrarosa, Femlyv, Femring |
| Channel Medsystems, INC. | $182.14 | 2022 | |
| Organon LLC | $135.75 | 2021-2025 | Nexplanon |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optumhealth Care Solutions, LLC | $126.49 | 2023-2025 | Eitan Medical, Vivify Health Care Team Portal 001, Vivify Health Care Team Portal |
| Pfizer INC. | $109.51 | 2021-2022 | |
| Daiichi Sankyo INC. | $104.95 | 2022-2024 | Injectafer |
| Evofem Biosciences, INC. | $101.36 | 2021-2023 | Phexxi |
| Agile Therapeutics, INC. | $96.37 | 2021-2022 | |
| Allergan, INC. | $89.00 | 2019 | |
| Avion Pharmaceuticals | $77.47 | 2019-2022 | |
| Covidien LP | $71.23 | 2020 | |
| Mylan Pharmaceuticals INC. | $69.80 | 2021-2022 | |
| Coopersurgical, INC. | $64.82 | 2020-2023 | Endosee |
| Amag Pharmaceuticals, INC. | $51.87 | 2019 | |
| Smith+Nephew, INC. | $51.32 | 2023-2025 | Stravix |
| Myriad Women'S Health, INC. | $51.13 | 2023 | Myrisk |
| Merck Sharp & Dohme LLC | $42.55 | 2020-2021 | |
| Axonics, INC. | $37.38 | 2022-2023 | Axonics |
| Duchesnay USA Incorporated | $34.63 | 2019-2020 | |
| Sanofi Pasteur INC. | $33.96 | 2025 | |
| Lupin INC. | $28.20 | 2019 | |
| Aspira Women'S Health INC | $23.90 | 2023-2024 | Ova1 |
| Takeda Pharmaceuticals U.S.A., INC. | $23.63 | 2022 | |
| Minerva Surgical, INC | $23.59 | 2025 | |
| Davol INC. | $21.75 | 2021 | |
| Sanara Medtech INC. | $21.34 | 2025 | Celleraterx |
| Conmed Corporation | $20.92 | 2025 | Airseal |
| Myovant Sciences INC. | $20.88 | 2021 | |
| Amgen INC. | $15.36 | 2025 | Prolia, Evenity |
| Ferring Pharmaceuticals INC. | $13.81 | 2020 | |
| Olympus America INC. | $13.36 | 2023 | Olympus |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$2.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Parry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.